Free Trial

Integra LifeSciences (IART) Stock Price, News & Analysis

$19.76
-0.04 (-0.20%)
(As of 10/17/2024 ET)

About Integra LifeSciences Stock (NASDAQ:IART)

Key Stats

Today's Range
$19.14
$19.84
50-Day Range
$16.95
$21.86
52-Week Range
$16.81
$45.42
Volume
719,873 shs
Average Volume
1.11 million shs
Market Capitalization
$1.56 billion
P/E Ratio
68.14
Dividend Yield
N/A
Price Target
$26.50
Consensus Rating
Reduce

Company Overview

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Integra LifeSciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
99th Percentile Overall Score

IART MarketRank™: 

Integra LifeSciences scored higher than 99% of companies evaluated by MarketBeat, and ranked 16th out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Integra LifeSciences has received a consensus rating of Reduce. The company's average rating score is 1.89, and is based on 2 buy ratings, 4 hold ratings, and 3 sell ratings.

  • Amount of Analyst Coverage

    Integra LifeSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Integra LifeSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Integra LifeSciences are expected to grow by 1.22% in the coming year, from $2.45 to $2.48 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Integra LifeSciences is 68.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.48.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Integra LifeSciences is 68.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 144.30.

  • Price to Earnings Growth Ratio

    Integra LifeSciences has a PEG Ratio of 0.62. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Integra LifeSciences has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Integra LifeSciences' valuation and earnings.
  • Percentage of Shares Shorted

    6.76% of the float of Integra LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Integra LifeSciences has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Integra LifeSciences has recently decreased by 3.72%, indicating that investor sentiment is improving.
  • Dividend Yield

    Integra LifeSciences does not currently pay a dividend.

  • Dividend Growth

    Integra LifeSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.76% of the float of Integra LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Integra LifeSciences has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Integra LifeSciences has recently decreased by 3.72%, indicating that investor sentiment is improving.
  • News Sentiment

    Integra LifeSciences has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Integra LifeSciences this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for IART on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Integra LifeSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Integra LifeSciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.10% of the stock of Integra LifeSciences is held by insiders.

  • Percentage Held by Institutions

    84.78% of the stock of Integra LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Integra LifeSciences' insider trading history.
Receive IART Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

IART Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
See More Headlines

IART Stock Analysis - Frequently Asked Questions

Integra LifeSciences' stock was trading at $43.55 at the start of the year. Since then, IART stock has decreased by 54.6% and is now trading at $19.76.
View the best growth stocks for 2024 here
.

Integra LifeSciences Holdings Co. (NASDAQ:IART) released its quarterly earnings data on Monday, July, 29th. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.01. Integra LifeSciences's revenue for the quarter was up 9.7% compared to the same quarter last year.

Integra LifeSciences's stock split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were issued to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Integra LifeSciences subsidiaries include these companies: ACell Inc, Rebound Therapeutics, Arkis BioSciences, Codman Neuro, TGX Medical Systems, Derma Sciences, Tekmed Instruments S.p.A, and more.

Integra LifeSciences' top institutional shareholders include Wedge Capital Management L L P NC (0.09%), Exchange Traded Concepts LLC (0.04%), SG Americas Securities LLC (0.04%) and Handelsbanken Fonder AB (0.03%). Insiders that own company stock include Stuart Essig, Glenn Coleman, Raymond G Murphy, Michael J Mcbreen, Lisa Evoli, Witte Jan De, Jeffrey Mosebrook and Tru St Partnership, LP.
View institutional ownership trends
.

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Integra LifeSciences investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Tesla (TSLA) and Home Depot (HD).

Company Calendar

Last Earnings
7/29/2024
Today
10/17/2024
Next Earnings (Confirmed)
11/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IART
CUSIP
45798520
Employees
3,946
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$26.50
High Stock Price Target
$50.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+34.1%
Consensus Rating
Reduce
Rating Score (0-4)
1.89
Research Coverage
9 Analysts

Profitability

Net Income
$67.74 million
Pretax Margin
1.73%

Debt

Sales & Book Value

Annual Sales
$1.57 billion
Cash Flow
$5.27 per share
Book Value
$20.31 per share

Miscellaneous

Free Float
75,177,000
Market Cap
$1.56 billion
Optionable
Optionable
Beta
1.09

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:IART) was last updated on 10/18/2024 by MarketBeat.com Staff
From Our Partners